Allogene Therapeutics, Inc.

Principal Financial Officer Appointment

In connection with the previously announced retirement of Geoffrey Parker from his position as Executive Vice President, Chief Financial Officer and principal financial officer, on November 3, 2026, our board of directors appointed Annie Yoshiyama, our current Senior Vice President, Corporate Controller and principal accounting officer, as principal financial officer of the Company, to be effective upon Mr. Parker’s retirement.

Ms. Yoshiyama, age 43, has served as our Senior Vice President, Finance and Corporate Controller since April 2024 and our principal accounting officer since June 2024. Prior to joining the Company in April 2024, Ms. Yoshiyama, served as Vice President, Finance & Controller at AN2 Therapeutics, Inc. from September 2023 to March 2024; Senior Vice President ‒ Finance and Chief Accounting Officer, Vice President ‒ Finance and Chief Accounting Officer, Executive Director ‒ Finance, Senior Director ‒ Finance, Director ‒ SEC Reporting and Technical Accounting, and Associate Director ‒ SEC Reporting and Technical Accounting at Tricida, Inc. from June 2018 to March 2023; Senior Financial Reporting and Technical Accounting Manager at Dolby Laboratories from September 2008 to June 2018; and started her career in audit at PricewaterhouseCoopers LLP from September 2005 to August 2007. Ms. Yoshiyama earned her Bachelor of Science and Master of Accounting degrees from the University of Southern California and is a licensed certified public accountant.

Trading Arrangements

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.